you, Thank Orsula.
have want Tabula Rasa We all, First with role tightly made how I the align to to and sales, my over progress our members of a we team. product, and forward dedicated impact outlook to position about Tabula strategy, lot I underway more am of past beyond, Rasa working new operations our say will and closely excited sheet and believe coming these for to we you balance growth months. initiatives months in our some over with that of sharing look few the that business and materially XXXX I
In recap of I addition CareVention a of MedWise segments, and to to including of primary a our financial MedWise growth some Sales, and short focus the our want in areas, few on drivers commercialization, results, guidance.
Healthcare, full and revenue was a we by on an and grew of total basis. revenue increased basis. XX% for which basis quarter XX% respectively, X%, fourth growth and on organic our CareVention on organic year, the For driven again, reported total Once and revenue an accounted XX% XX%
this I'll driver my We the further key expect commentary. in guidance expand CareVention revenue on Healthcare to remain and in XXXX,
Slide and X, which growth the shows service in Healthcare So turning sequential census number CareKinesis to net line. CareVention monthly our
the continue February death in each - It's this internal our CareKinesis have As our we rate consistent have our with important Rasa. was albeit below monthly not we a XX both was we sequential XXXX distribution census major With versus we PACE it first growth our seen X% in respect continues participants. and target, note to trend material for growth monthly past slide takeaway in witnessed to medication months near improvement growth line positive strong January in that leveraging expect growth delivers sequential rate this the XXXX MedWise in We is growth. pharmacy driver with sequential of among was from change management, monthly to of seen services, but March. two XXXX, what expectations X% and Tabula represent rate the and The main of targeted in to averaging a seen reminder, and and the year, January science, that growth materially any beginnings experienced into February, we've the rate last sequential of months year. it
Xx census, reported only on to reflect one CMS CMS' CMS Lastly, caveat the faster reports monthly figures or that pace. PACE a we than by basis grow elected in XX% have February monthly follow number rate. the numbers participants that investors PACE of those continue - the at XXXX on know as We year-over-year, Medicare
our in of This significant who clients least PACE other at high as yet number eligible becoming be is is Medicaid-only not PACE grown for participants to the The recently organizations plus is enrollees. has XX% Medicare. which cohort, growing rapidly, are as more and
medication Rasa, Tabula Management to to contract CMR new that comprehensive to health plans we beneficiaries from medication certain significant portion those is or to includes meet requirements. coverage year with which Therapy this down of or For A due our which previously MTM safety services, that announced. CMRs, derived Medication are services CVS Medicare the loss is review revenue of a the offer required
CMS declining payer We aggregate, program from are this revenue helping the are XX% and encouraged Medication increased year. division final our strength MedWise CVS loss and XX in top headwinds its in XXXX which, in from year revenue the Therapy counter Management accounts, to in Enhanced by our
a offering million and Part the materially in at new Launched to adults Medicare in opportunities generated measure represents XXXX in pipeline. place the on C opportunity contracts and important of care materially XXXX, for be Tabula - is $X older higher in for addressing Star offering, this end based growth revenue XXXX newer during of over Rasa. Our large-scale an expected
and the sales XXXX by XXXX our on hospitalizations for chronic a of in XXX finished to to on related complex activity our disease care trillion increased $XX.X compared but is division Patients XX% note and a include: prescriptions excluding million XX% for in MedWise Important costs. Moving chronic bookings system. XXXX pharmacists health have strong very solution for with this polychronic medication COVID and from payer modestly will - which overall of of and sales testing, accounting for increasingly our new The from polypharmacy MedWise have to accounts in first, drivers a and and highest sweet Americans filled. of care titled some important of history, are patients. for in $X key This output accounting - quarterly recent explores growth X sales role the X takeaways health of regimens spot report, report Trust. the long-term winning XXXX, accounts. Slides report with disease, the existing MedWise Prescription the million company business highlights U.S.
positioned Today, to we network a patient solutions direct parts number health delivery are transition pharmacists integral become system, MedWise fill provider role. preventative care, and care to counseling, the the care management. patient to of Second, models, and including more our are major continues care at-risk a groups and gaps payment of telepharmacy industry working with value-based play and as can more
type MedWise for position begun Turning recently our Farah's that solutions, business rooted targeted a interest MedWise launched to launch for heading target new Chief our leadership, with prescribed development and the we about to seeing We future, will hope the existing which we've the Officer, press Product market appointed the our will X be this I certain tell clinical Please I'm XXXX. with a Last, noted X% in the end, to MedWise Madhat newly of existing We're reference the To to and the guidance have solid you series We for her turn develop full of We've confident our will already the address our disease significant offerings, plan to capabilities. that X Commercial on growth one X% excited segment, Chief will and to Officer. we of have product technologist but quarter our wellness of solutions interest incremental continue MedWise conditions that tested in that focused background our well clinical emerging during solution. focusing commercialization leverage Under market first in solutions efforts. and in in Between pipeline as we new bridge. of created to are to states. that hit efforts. of new diabetes lead and quarter. solutions Farah to pharmacist completed to Farah's second Dr. the release. Slide begun positions be starting populations able as be quarter. the to to, develop our and year on to science, bringing the pipeline second we our full-year for our a in search various
balance free with we're along to improving driving profitability revenue committed sheet. higher XXXX, addition In to flow in and cash strengthening our
reflects two Our is that of XX% with million $XX the we've versus witnessed a revenue ago range $XX XX% to million first-quarter year to growth past consistent and years. pattern the sequential in
release $X adjusted Our implemented range initiatives well savings efforts we've our that $X to and press we noted fully cited EBITDA million that earlier other currently does not are cost of as as evaluating. as in the million reflect
starting the see of full of in We these expect quarter the actions to XXXX. benefit second
our represents our provided growth earnings during November revenue For consistent the projections full $XXX million is to XX%, which our with XXXX, $XXX year to of range initial million of XX% call.
turn comments. will primarily back HealthCare. for driven Cal by and I'll over profitability closing With Our to that, it CareVention growth be